Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 19;23(10):5680.
doi: 10.3390/ijms23105680.

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

Affiliations
Review

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

Farah Omran et al. Int J Mol Sci. .

Abstract

Cardiovascular diseases (CVDs) are a major healthcare burden on the population worldwide. Early detection of this disease is important in prevention and treatment to minimise morbidity and mortality. Biomarkers are a critical tool to either diagnose, screen, or provide prognostic information for pathological conditions. This review discusses the historical cardiac biomarkers used to detect these conditions, discussing their application and their limitations. Identification of new biomarkers have since replaced these and are now in use in routine clinical practice, but still do not detect all disease. Future cardiac biomarkers are showing promise in early studies, but further studies are required to show their value in improving detection of CVD above the current biomarkers. Additionally, the analytical platforms that would allow them to be adopted in healthcare are yet to be established. There is also the need to identify whether these biomarkers can be used for diagnostic, prognostic, or screening purposes, which will impact their implementation in routine clinical practice.

Keywords: biomarkers; cardiovascular diseases; future biomarkers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. World Health Organization (WHO) Cardiovascular Diseases (CVDs) 2021. [(accessed on 11 June 2021)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases...
    1. Behera S., Pramanik K., Nayak M. Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology. Curr. Pharm. Des. 2015;21:4479–4497. doi: 10.2174/1381612821666150817104635. - DOI - PubMed
    1. Aronson J.K., Ferner R.E. Biomarkers—A general review. Curr. Protoc. Pharmacol. 2017;2017:9.23.1–9.23.17. doi: 10.1002/cpph.19. - DOI - PubMed
    1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001;69:89–95. doi: 10.1067/mcp.2001.113989. - DOI - PubMed
    1. Strimbu K., Tavel J.A. What are biomarkers? Curr. Opin. HIV AIDS. 2010;5:463–466. doi: 10.1097/COH.0b013e32833ed177. - DOI - PMC - PubMed

LinkOut - more resources